Forbius   Report issue

For profit Phase 1
Founded: Austin TX United States (2011)

Organization Overview

First Clinical Trial
2017
NCT03094169
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Forbius (Formation Biologics) | Formation Biologics

Active Ingredients

Drugs in Phase 1 Trials (2)

avid100 (1 trial)

avid200 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Neoplasms (Phase 1)

Polycythemia (Phase 1)

Polycythemia Vera (Phase 1)

Primary Myelofibrosis (Phase 1)

Scleroderma, Diffuse (Phase 1)

Scleroderma, Systemic (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 1)

Thrombocythemia, Essential (Phase 1)

Thrombocytosis (Phase 1)

Triple Negative Breast Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 4
  • # of Trial APIs: 2